Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -190,600 | -760,500 | -211,600 | 219,500 | 305,100 |
| Depreciation Amortization | 116,200 | 364,600 | 154,100 | 169,600 | 118,000 |
| Income taxes - deferred | -5,500 | -8,900 | -28,600 | 46,000 | -2,400 |
| Accounts receivable | -24,400 | -21,600 | 118,100 | -16,200 | 49,000 |
| Accounts payable and accrued liabilities | -33,000 | 10,600 | -14,000 | -1,600 | 18,700 |
| Other Working Capital | 85,100 | -75,100 | -2,100 | -145,000 | 8,800 |
| Other Operating Activity | 110,900 | 284,600 | -50,000 | 47,900 | 38,800 |
| Operating Cash Flow | $58,700 | $-206,300 | $-34,100 | $320,200 | $536,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -15,000 | -51,600 | -115,800 | -224,100 | -141,000 |
| Net Acquisitions | 110,200 | 270,200 | -243,700 | N/A | N/A |
| Purchase Sale Intangibles | 0 | 0 | -21,800 | 0 | 0 |
| Other Investing Activity | 30,000 | -6,300 | -21,800 | 0 | -10,000 |
| Investing Cash Flow | $125,200 | $212,300 | $-381,300 | $-224,100 | $-151,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 284,000 | 20,000 | 598,000 | -25,300 | 435,900 |
| Debt Repayment | -482,400 | -563,400 | -33,800 | -10,600 | -373,000 |
| Common Stock Issued | 22,700 | 0 | 0 | N/A | N/A |
| Common Stock Repurchased | N/A | N/A | -82,100 | -106,000 | N/A |
| Other Financing Activity | -14,300 | 7,700 | -900 | 900 | 6,600 |
| Financing Cash Flow | $-190,000 | $-535,700 | $481,200 | $-141,000 | $69,500 |
| Exchange Rate Effect | 0 | -1,200 | 500 | -300 | -1,000 |
| Beginning Cash Position | 111,700 | 642,600 | 576,300 | 621,500 | 168,000 |
| End Cash Position | 105,600 | 111,700 | 642,600 | 576,300 | 621,500 |
| Net Cash Flow | $-6,100 | $-530,900 | $66,300 | $-45,200 | $453,500 |
| Free Cash Flow | |||||
| Operating Cash Flow | 58,700 | -206,300 | -34,100 | 320,200 | 536,000 |
| Capital Expenditure | -22,900 | -51,600 | -115,800 | -224,100 | -141,000 |
| Free Cash Flow | 35,800 | -257,900 | -149,900 | 96,100 | 395,000 |